Reported benefits (per available research): Studied for restoring more youthful pulsatile GH and IGF-1 secretion in older adults, based on a small 1997 randomized, placebo-controlled human trial of a closely related GHRH(1-29) analog published in the Journal of Clinical Endocrinology & Metabolism May support gains in lean body mass in men specifically: that same 16-week trial found a statistically significant increase in lean body mass in men but not in women, alongside a significant increase in skin thickness (a marker of dermal collagen) in both sexes Proposed to support broader recovery and body-composition goals tied to growth-hormone-axis activity, though sermorelin-specific modern adult trial data remains thin, and much of the anti-aging and muscle-building framing used in commercial marketing outpaces the current clinical evidence base Known risks and side effects: Injection-site reactions (pain, swelling, or redness) are the most commonly reported adverse event associated with sermorelin therapy in manufacturer drug-labeling data Headache, flushing, dizziness, difficulty swallowing, hyperactivity, drowsiness, and hives have also been reported less commonly per that same labeling data
In vivo and ex vivo imaging of brain-targeted properties Although the BBB is essential for maintaining the proper function of the CNS, it also poses significant challenges for treating neurological disorders, such as AD [68]
ERT is also potentially limited by reaccumulation of Gb3 in podocytes after dose adjustment during the follow-up period and formation of neutralizing antidrug antibodies after infusion, which reduce the efficacy of ERT by increasing cellular Gb3 deposition and results in harmful clinical outcomes that include progressive loss of renal function 13,14
Metabolism Clinical and Experimental, 144 , 155533
